CareDx, Inc. CDNA revealed promising clinical performance of its AlloSure assay for the non-invasive surveillance of kidney transplant rejection, according to a note from analysts at Janney.
In patients studied as part of a DART clinical trial, CareDx’s “AlloSure” blood assay successfully detected heightened levels of donor-derived cell free DNA in subjects presenting kidney transplant rejection.
More details could follow if AlloSure is presented during kidney week at the American Society of Nephrologists this fall. Leveraging on the company's transplantation expertise and existing relationships cultivated over a multi-year period, cross-selling opportunities and new product rollouts may drive revenue acceleration starting in 2017.
CareDx closed up 2 percent at $5.04 Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
